img

Global Radionuclide Drug Conjugates (RDC) Market Research Report 2024

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global Radionuclide Drug Conjugates (RDC) Market Research Report 2024

According to MRAResearch’s new survey, global Radionuclide Drug Conjugates (RDC) market is projected to reach US$ million in 2033, increasing from US$ million in 2022, with the CAGR of % during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Radionuclide Drug Conjugates (RDC) market research.
RDC therapy combines radionuclides with specific monoclonal antibodies to achieve the dual advantages of precise targeting and powerful killing of tumor cells. It can highly concentrate the energy released by radionuclides within several times the diameter of cancer cells, thereby minimizing damage to surrounding normal tissues. This enables it to effectively kill cancer cells while protecting normal tissues, so it has good curative effect and low adverse reactions, and can prolong the survival of patients with advanced cancer, which is of great significance to the treatment of advanced tumors.
According to the function, RDC can be divided into RDC for diagnosis and RDC for treatment, and the functional classification is closely related to the type of nuclide.
At present, the most widely used nuclide for diagnosis is 99mTc, and the nuclide for treatment is 131I, 90Y and 223Ra. Radionuclide technology provides unique advantages for early diagnosis and targeted therapy of tumors, but the acquisition and preparation technology of radionuclide still limits its wider clinical application and needs further research and development.
According to different targeting ligands, RDC can be subdivided intoantibody-conjugated nuclide drugs (ARC) and small molecule-conjugated nuclide drugs (including polypeptide-conjugated nuclide drugs-PRC).
According to the data of the Global New Drug Information Database, among the RDC drugs currently in clinical research and on the market, the main research targets are CAIX (carbonic anhydrase IX), PSMA (prostate-specific membrane antigen), SSTR (somatostatin receptor ); the main indications are concentrated in neuroendocrine tumors, prostate cancer, and renal cell carcinoma.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Radionuclide Drug Conjugates (RDC) market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.



By Company


POINT Biopharma
Telix
ITM AG
Bayer AG
Novartis
Lantheus
Curium Pharma
Uihc Pet Imaging
Grand Pharma
BoomRay Pharmaceuticals
SmartNuclide Biopharma
Hengrui Medicine
Yunnan Baiyao Group
Sinotau
Hexin Pharmaceutical
Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.
Segment by Type
Antibody Radionuclide Conjugates (ARC)
Peptide Radionuclide Conjugates (PRC)
Small Molecular Radionuclide Conjugates (SMRC)

Segment by Application


Neuroendocrine Tumors
Prostate Cancer
Renal Cell Carcinoma
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Radionuclide Drug Conjugates (RDC) report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Type: 2018 VS 2022 VS 2033
1.2.2 Antibody Radionuclide Conjugates (ARC)
1.2.3 Peptide Radionuclide Conjugates (PRC)
1.2.4 Small Molecular Radionuclide Conjugates (SMRC)
1.3 Market by Application
1.3.1 Global Radionuclide Drug Conjugates (RDC) Market Growth by Application: 2018 VS 2022 VS 2033
1.3.2 Neuroendocrine Tumors
1.3.3 Prostate Cancer
1.3.4 Renal Cell Carcinoma
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Radionuclide Drug Conjugates (RDC) Market Perspective (2018-2033)
2.2 Radionuclide Drug Conjugates (RDC) Growth Trends by Region
2.2.1 Global Radionuclide Drug Conjugates (RDC) Market Size by Region: 2018 VS 2022 VS 2033
2.2.2 Radionuclide Drug Conjugates (RDC) Historic Market Size by Region (2018-2023)
2.2.3 Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Region (2024-2033)
2.3 Radionuclide Drug Conjugates (RDC) Market Dynamics
2.3.1 Radionuclide Drug Conjugates (RDC) Industry Trends
2.3.2 Radionuclide Drug Conjugates (RDC) Market Drivers
2.3.3 Radionuclide Drug Conjugates (RDC) Market Challenges
2.3.4 Radionuclide Drug Conjugates (RDC) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Radionuclide Drug Conjugates (RDC) Players by Revenue
3.1.1 Global Top Radionuclide Drug Conjugates (RDC) Players by Revenue (2018-2023)
3.1.2 Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Players (2018-2023)
3.2 Global Radionuclide Drug Conjugates (RDC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Radionuclide Drug Conjugates (RDC) Revenue
3.4 Global Radionuclide Drug Conjugates (RDC) Market Concentration Ratio
3.4.1 Global Radionuclide Drug Conjugates (RDC) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Radionuclide Drug Conjugates (RDC) Revenue in 2022
3.5 Radionuclide Drug Conjugates (RDC) Key Players Head office and Area Served
3.6 Key Players Radionuclide Drug Conjugates (RDC) Product Solution and Service
3.7 Date of Enter into Radionuclide Drug Conjugates (RDC) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Radionuclide Drug Conjugates (RDC) Breakdown Data by Type
4.1 Global Radionuclide Drug Conjugates (RDC) Historic Market Size by Type (2018-2023)
4.2 Global Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Type (2024-2033)
5 Radionuclide Drug Conjugates (RDC) Breakdown Data by Application
5.1 Global Radionuclide Drug Conjugates (RDC) Historic Market Size by Application (2018-2023)
5.2 Global Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Application (2024-2033)
6 North America
6.1 North America Radionuclide Drug Conjugates (RDC) Market Size (2018-2033)
6.2 North America Radionuclide Drug Conjugates (RDC) Market Growth Rate by Country: 2018 VS 2022 VS 2033
6.3 North America Radionuclide Drug Conjugates (RDC) Market Size by Country (2018-2023)
6.4 North America Radionuclide Drug Conjugates (RDC) Market Size by Country (2024-2033)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Radionuclide Drug Conjugates (RDC) Market Size (2018-2033)
7.2 Europe Radionuclide Drug Conjugates (RDC) Market Growth Rate by Country: 2018 VS 2022 VS 2033
7.3 Europe Radionuclide Drug Conjugates (RDC) Market Size by Country (2018-2023)
7.4 Europe Radionuclide Drug Conjugates (RDC) Market Size by Country (2024-2033)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size (2018-2033)
8.2 Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Growth Rate by Region: 2018 VS 2022 VS 2033
8.3 Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size by Region (2018-2023)
8.4 Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size by Region (2024-2033)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Radionuclide Drug Conjugates (RDC) Market Size (2018-2033)
9.2 Latin America Radionuclide Drug Conjugates (RDC) Market Growth Rate by Country: 2018 VS 2022 VS 2033
9.3 Latin America Radionuclide Drug Conjugates (RDC) Market Size by Country (2018-2023)
9.4 Latin America Radionuclide Drug Conjugates (RDC) Market Size by Country (2024-2033)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size (2018-2033)
10.2 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Growth Rate by Country: 2018 VS 2022 VS 2033
10.3 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Country (2018-2023)
10.4 Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Country (2024-2033)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 POINT Biopharma
11.1.1 POINT Biopharma Company Detail
11.1.2 POINT Biopharma Business Overview
11.1.3 POINT Biopharma Radionuclide Drug Conjugates (RDC) Introduction
11.1.4 POINT Biopharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.1.5 POINT Biopharma Recent Development
11.2 Telix
11.2.1 Telix Company Detail
11.2.2 Telix Business Overview
11.2.3 Telix Radionuclide Drug Conjugates (RDC) Introduction
11.2.4 Telix Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.2.5 Telix Recent Development
11.3 ITM AG
11.3.1 ITM AG Company Detail
11.3.2 ITM AG Business Overview
11.3.3 ITM AG Radionuclide Drug Conjugates (RDC) Introduction
11.3.4 ITM AG Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.3.5 ITM AG Recent Development
11.4 Bayer AG
11.4.1 Bayer AG Company Detail
11.4.2 Bayer AG Business Overview
11.4.3 Bayer AG Radionuclide Drug Conjugates (RDC) Introduction
11.4.4 Bayer AG Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.4.5 Bayer AG Recent Development
11.5 Novartis
11.5.1 Novartis Company Detail
11.5.2 Novartis Business Overview
11.5.3 Novartis Radionuclide Drug Conjugates (RDC) Introduction
11.5.4 Novartis Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.5.5 Novartis Recent Development
11.6 Lantheus
11.6.1 Lantheus Company Detail
11.6.2 Lantheus Business Overview
11.6.3 Lantheus Radionuclide Drug Conjugates (RDC) Introduction
11.6.4 Lantheus Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.6.5 Lantheus Recent Development
11.7 Curium Pharma
11.7.1 Curium Pharma Company Detail
11.7.2 Curium Pharma Business Overview
11.7.3 Curium Pharma Radionuclide Drug Conjugates (RDC) Introduction
11.7.4 Curium Pharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.7.5 Curium Pharma Recent Development
11.8 Uihc Pet Imaging
11.8.1 Uihc Pet Imaging Company Detail
11.8.2 Uihc Pet Imaging Business Overview
11.8.3 Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Introduction
11.8.4 Uihc Pet Imaging Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.8.5 Uihc Pet Imaging Recent Development
11.9 Grand Pharma
11.9.1 Grand Pharma Company Detail
11.9.2 Grand Pharma Business Overview
11.9.3 Grand Pharma Radionuclide Drug Conjugates (RDC) Introduction
11.9.4 Grand Pharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.9.5 Grand Pharma Recent Development
11.10 BoomRay Pharmaceuticals
11.10.1 BoomRay Pharmaceuticals Company Detail
11.10.2 BoomRay Pharmaceuticals Business Overview
11.10.3 BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Introduction
11.10.4 BoomRay Pharmaceuticals Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.10.5 BoomRay Pharmaceuticals Recent Development
11.11 SmartNuclide Biopharma
11.11.1 SmartNuclide Biopharma Company Detail
11.11.2 SmartNuclide Biopharma Business Overview
11.11.3 SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Introduction
11.11.4 SmartNuclide Biopharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.11.5 SmartNuclide Biopharma Recent Development
11.12 Hengrui Medicine
11.12.1 Hengrui Medicine Company Detail
11.12.2 Hengrui Medicine Business Overview
11.12.3 Hengrui Medicine Radionuclide Drug Conjugates (RDC) Introduction
11.12.4 Hengrui Medicine Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.12.5 Hengrui Medicine Recent Development
11.13 Yunnan Baiyao Group
11.13.1 Yunnan Baiyao Group Company Detail
11.13.2 Yunnan Baiyao Group Business Overview
11.13.3 Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Introduction
11.13.4 Yunnan Baiyao Group Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.13.5 Yunnan Baiyao Group Recent Development
11.14 Sinotau
11.14.1 Sinotau Company Detail
11.14.2 Sinotau Business Overview
11.14.3 Sinotau Radionuclide Drug Conjugates (RDC) Introduction
11.14.4 Sinotau Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.14.5 Sinotau Recent Development
11.15 Hexin Pharmaceutical
11.15.1 Hexin Pharmaceutical Company Detail
11.15.2 Hexin Pharmaceutical Business Overview
11.15.3 Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Introduction
11.15.4 Hexin Pharmaceutical Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.15.5 Hexin Pharmaceutical Recent Development
11.16 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd.
11.16.1 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Company Detail
11.16.2 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Business Overview
11.16.3 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Introduction
11.16.4 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
11.16.5 Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2033
Table 2. Key Players of Antibody Radionuclide Conjugates (ARC)
Table 3. Key Players of Peptide Radionuclide Conjugates (PRC)
Table 4. Key Players of Small Molecular Radionuclide Conjugates (SMRC)
Table 5. Global Radionuclide Drug Conjugates (RDC) Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2033
Table 6. Global Radionuclide Drug Conjugates (RDC) Market Size by Region (US$ Million): 2018 VS 2022 VS 2033
Table 7. Global Radionuclide Drug Conjugates (RDC) Market Size by Region (2018-2023) & (US$ Million)
Table 8. Global Radionuclide Drug Conjugates (RDC) Market Share by Region (2018-2023)
Table 9. Global Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Region (2024-2033) & (US$ Million)
Table 10. Global Radionuclide Drug Conjugates (RDC) Market Share by Region (2024-2033)
Table 11. Radionuclide Drug Conjugates (RDC) Market Trends
Table 12. Radionuclide Drug Conjugates (RDC) Market Drivers
Table 13. Radionuclide Drug Conjugates (RDC) Market Challenges
Table 14. Radionuclide Drug Conjugates (RDC) Market Restraints
Table 15. Global Radionuclide Drug Conjugates (RDC) Revenue by Players (2018-2023) & (US$ Million)
Table 16. Global Radionuclide Drug Conjugates (RDC) Market Share by Players (2018-2023)
Table 17. Global Top Radionuclide Drug Conjugates (RDC) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radionuclide Drug Conjugates (RDC) as of 2022)
Table 18. Ranking of Global Top Radionuclide Drug Conjugates (RDC) Companies by Revenue (US$ Million) in 2022
Table 19. Global 5 Largest Players Market Share by Radionuclide Drug Conjugates (RDC) Revenue (CR5 and HHI) & (2018-2023)
Table 20. Key Players Headquarters and Area Served
Table 21. Key Players Radionuclide Drug Conjugates (RDC) Product Solution and Service
Table 22. Date of Enter into Radionuclide Drug Conjugates (RDC) Market
Table 23. Mergers & Acquisitions, Expansion Plans
Table 24. Global Radionuclide Drug Conjugates (RDC) Market Size by Type (2018-2023) & (US$ Million)
Table 25. Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Type (2018-2023)
Table 26. Global Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Type (2024-2033) & (US$ Million)
Table 27. Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Type (2024-2033)
Table 28. Global Radionuclide Drug Conjugates (RDC) Market Size by Application (2018-2023) & (US$ Million)
Table 29. Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Application (2018-2023)
Table 30. Global Radionuclide Drug Conjugates (RDC) Forecasted Market Size by Application (2024-2033) & (US$ Million)
Table 31. Global Radionuclide Drug Conjugates (RDC) Revenue Market Share by Application (2024-2033)
Table 32. North America Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 33. North America Radionuclide Drug Conjugates (RDC) Market Size by Country (2018-2023) & (US$ Million)
Table 34. North America Radionuclide Drug Conjugates (RDC) Market Size by Country (2024-2033) & (US$ Million)
Table 35. Europe Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 36. Europe Radionuclide Drug Conjugates (RDC) Market Size by Country (2018-2023) & (US$ Million)
Table 37. Europe Radionuclide Drug Conjugates (RDC) Market Size by Country (2024-2033) & (US$ Million)
Table 38. Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2033
Table 39. Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size by Region (2018-2023) & (US$ Million)
Table 40. Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size by Region (2024-2033) & (US$ Million)
Table 41. Latin America Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 42. Latin America Radionuclide Drug Conjugates (RDC) Market Size by Country (2018-2023) & (US$ Million)
Table 43. Latin America Radionuclide Drug Conjugates (RDC) Market Size by Country (2024-2033) & (US$ Million)
Table 44. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2033
Table 45. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Country (2018-2023) & (US$ Million)
Table 46. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size by Country (2024-2033) & (US$ Million)
Table 47. POINT Biopharma Company Detail
Table 48. POINT Biopharma Business Overview
Table 49. POINT Biopharma Radionuclide Drug Conjugates (RDC) Product
Table 50. POINT Biopharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 51. POINT Biopharma Recent Development
Table 52. Telix Company Detail
Table 53. Telix Business Overview
Table 54. Telix Radionuclide Drug Conjugates (RDC) Product
Table 55. Telix Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 56. Telix Recent Development
Table 57. ITM AG Company Detail
Table 58. ITM AG Business Overview
Table 59. ITM AG Radionuclide Drug Conjugates (RDC) Product
Table 60. ITM AG Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 61. ITM AG Recent Development
Table 62. Bayer AG Company Detail
Table 63. Bayer AG Business Overview
Table 64. Bayer AG Radionuclide Drug Conjugates (RDC) Product
Table 65. Bayer AG Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 66. Bayer AG Recent Development
Table 67. Novartis Company Detail
Table 68. Novartis Business Overview
Table 69. Novartis Radionuclide Drug Conjugates (RDC) Product
Table 70. Novartis Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 71. Novartis Recent Development
Table 72. Lantheus Company Detail
Table 73. Lantheus Business Overview
Table 74. Lantheus Radionuclide Drug Conjugates (RDC) Product
Table 75. Lantheus Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 76. Lantheus Recent Development
Table 77. Curium Pharma Company Detail
Table 78. Curium Pharma Business Overview
Table 79. Curium Pharma Radionuclide Drug Conjugates (RDC) Product
Table 80. Curium Pharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 81. Curium Pharma Recent Development
Table 82. Uihc Pet Imaging Company Detail
Table 83. Uihc Pet Imaging Business Overview
Table 84. Uihc Pet Imaging Radionuclide Drug Conjugates (RDC) Product
Table 85. Uihc Pet Imaging Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 86. Uihc Pet Imaging Recent Development
Table 87. Grand Pharma Company Detail
Table 88. Grand Pharma Business Overview
Table 89. Grand Pharma Radionuclide Drug Conjugates (RDC) Product
Table 90. Grand Pharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 91. Grand Pharma Recent Development
Table 92. BoomRay Pharmaceuticals Company Detail
Table 93. BoomRay Pharmaceuticals Business Overview
Table 94. BoomRay Pharmaceuticals Radionuclide Drug Conjugates (RDC) Product
Table 95. BoomRay Pharmaceuticals Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 96. BoomRay Pharmaceuticals Recent Development
Table 97. SmartNuclide Biopharma Company Detail
Table 98. SmartNuclide Biopharma Business Overview
Table 99. SmartNuclide Biopharma Radionuclide Drug Conjugates (RDC) Product
Table 100. SmartNuclide Biopharma Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 101. SmartNuclide Biopharma Recent Development
Table 102. Hengrui Medicine Company Detail
Table 103. Hengrui Medicine Business Overview
Table 104. Hengrui Medicine Radionuclide Drug Conjugates (RDC) Product
Table 105. Hengrui Medicine Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 106. Hengrui Medicine Recent Development
Table 107. Yunnan Baiyao Group Company Detail
Table 108. Yunnan Baiyao Group Business Overview
Table 109. Yunnan Baiyao Group Radionuclide Drug Conjugates (RDC) Product
Table 110. Yunnan Baiyao Group Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 111. Yunnan Baiyao Group Recent Development
Table 112. Sinotau Company Detail
Table 113. Sinotau Business Overview
Table 114. Sinotau Radionuclide Drug Conjugates (RDC) Product
Table 115. Sinotau Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 116. Sinotau Recent Development
Table 117. Hexin Pharmaceutical Company Detail
Table 118. Hexin Pharmaceutical Business Overview
Table 119. Hexin Pharmaceutical Radionuclide Drug Conjugates (RDC) Product
Table 120. Hexin Pharmaceutical Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 121. Hexin Pharmaceutical Recent Development
Table 122. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Company Detail
Table 123. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Business Overview
Table 124. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Radionuclide Drug Conjugates (RDC) Product
Table 125. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Revenue in Radionuclide Drug Conjugates (RDC) Business (2018-2023) & (US$ Million)
Table 126. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Recent Development
Table 127. Research Programs/Design for This Report
Table 128. Key Data Information from Secondary Sources
Table 129. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Radionuclide Drug Conjugates (RDC) Market Size Comparison by Type (2023-2033) & (US$ Million)
Figure 2. Global Radionuclide Drug Conjugates (RDC) Market Share by Type: 2022 VS 2033
Figure 3. Antibody Radionuclide Conjugates (ARC) Features
Figure 4. Peptide Radionuclide Conjugates (PRC) Features
Figure 5. Small Molecular Radionuclide Conjugates (SMRC) Features
Figure 6. Global Radionuclide Drug Conjugates (RDC) Market Size Comparison by Application (2023-2033) & (US$ Million)
Figure 7. Global Radionuclide Drug Conjugates (RDC) Market Share by Application: 2022 VS 2033
Figure 8. Neuroendocrine Tumors Case Studies
Figure 9. Prostate Cancer Case Studies
Figure 10. Renal Cell Carcinoma Case Studies
Figure 11. Radionuclide Drug Conjugates (RDC) Report Years Considered
Figure 12. Global Radionuclide Drug Conjugates (RDC) Market Size (US$ Million), Year-over-Year: 2018-2033
Figure 13. Global Radionuclide Drug Conjugates (RDC) Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 14. Global Radionuclide Drug Conjugates (RDC) Market Share by Region: 2022 VS 2033
Figure 15. Global Radionuclide Drug Conjugates (RDC) Market Share by Players in 2022
Figure 16. Global Top Radionuclide Drug Conjugates (RDC) Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Radionuclide Drug Conjugates (RDC) as of 2022)
Figure 17. The Top 10 and 5 Players Market Share by Radionuclide Drug Conjugates (RDC) Revenue in 2022
Figure 18. North America Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 19. North America Radionuclide Drug Conjugates (RDC) Market Share by Country (2018-2033)
Figure 20. United States Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 21. Canada Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 22. Europe Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 23. Europe Radionuclide Drug Conjugates (RDC) Market Share by Country (2018-2033)
Figure 24. Germany Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 25. France Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 26. U.K. Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 27. Italy Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 28. Russia Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 29. Nordic Countries Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 30. Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 31. Asia-Pacific Radionuclide Drug Conjugates (RDC) Market Share by Region (2018-2033)
Figure 32. China Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 33. Japan Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 34. South Korea Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 35. Southeast Asia Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 36. India Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 37. Australia Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 38. Latin America Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 39. Latin America Radionuclide Drug Conjugates (RDC) Market Share by Country (2018-2033)
Figure 40. Mexico Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 41. Brazil Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 42. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 43. Middle East & Africa Radionuclide Drug Conjugates (RDC) Market Share by Country (2018-2033)
Figure 44. Turkey Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 45. Saudi Arabia Radionuclide Drug Conjugates (RDC) Market Size YoY Growth (2018-2033) & (US$ Million)
Figure 46. POINT Biopharma Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 47. Telix Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 48. ITM AG Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 49. Bayer AG Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 50. Novartis Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 51. Lantheus Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 52. Curium Pharma Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 53. Uihc Pet Imaging Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 54. Grand Pharma Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 55. BoomRay Pharmaceuticals Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 56. SmartNuclide Biopharma Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 57. Hengrui Medicine Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 58. Yunnan Baiyao Group Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 59. Sinotau Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 60. Hexin Pharmaceutical Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 61. Shenzhen Jianyuan Pharmaceutical Technology Co., Ltd. Revenue Growth Rate in Radionuclide Drug Conjugates (RDC) Business (2018-2023)
Figure 62. Bottom-up and Top-down Approaches for This Report
Figure 63. Data Triangulation
Figure 64. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries